Modified Thalidomide Selectively Degrades an 'Undruggable' Transcription Factor
- Researchers report that 5-tBu-thalidomide, a chemically modified thalidomide analog, acts as a molecular glue that recruits the CRBN E3 ligase to drive potent, selective breakdown of FIZ1, a zinc-finger transcription factor linked to FLT3 signaling.
- FIZ1 contains eleven zinc-finger domains, several of which carry the degron sequence normally required for thalidomide-class drugs to engage, yet the compound acts almost exclusively through a single finger, zinc finger 8.
- Computational modeling of the CRBN–drug–FIZ1 ternary complex reveals the contacts that favor this domain over the others, explaining the selectivity.
- The work offers a template for rationally designing thalidomide-based glues that target individual zinc fingers within otherwise 'undruggable' transcription factors.
A single tert-butyl group turning thalidomide into a ZF8-selective glue is the kind of result that makes you go back and stare at your own IMiD SAR data — this is minimal medicinal chemistry, not a redesigned scaffold, and that's the exciting part. The real puzzle is why one finger out of eleven degron-competent copies wins. If the ternary-complex modeling holds up, this is a rare case where computation actually explains selectivity instead of rationalizing it after the fact. IMiD-class glues have a promiscuity problem — off-target zinc fingers are exactly how thalidomide's teratogenicity got explained via SALL4. A route to finger-specific engagement is the fix chemists have wanted since that story broke. I'd want a neosubstrate panel run immediately: does 5-tBu still hit SALL4/IKZF1/GSPT1, or did this substitution buy clean selectivity for free? That answer decides whether this is a platform or a one-off.